NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Maravai LifeSciences Holdings Inc. reported a net loss of $69.8 million for the second quarter of 2025.
Revenue declined 31.7% year-over-year to $47.4 million, primarily due to the absence of high-volume CleanCap sales for commercial vaccine programs. The company recorded $30.4 million in goodwill impairment within its Nucleic Acid Production segment and reported Adjusted EBITDA of negative $10.4 million. Cash and cash equivalents stood at $269.9 million at quarter end.
- Nucleic Acid Production revenue fell 43.1% to $31.1 million, driven by zero high-volume CleanCap orders compared to $24.4 million in Q2 2024.
- Biologics Safety Testing revenue grew 9.9% to $16.3 million, supported by demand for HCP kits and MockV viral clearance products.
- Goodwill impairment of $30.4 million was recognized for the Alphazyme reporting unit amid lower projected enzyme demand.
- Net loss per Class A share was $(0.27), with total operating expenses rising to $113.7 million including the impairment charge.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$47.4M
Revenue by segment
Maravai · $47.4M total across 2 segments · Q2 2025
- Nucleic Acid Production$31.1M—65.6%
- Biologics Safety Testing$16.3M—34.4%
Forward guidance
The company continues to face headwinds from the absence of commercial CleanCap revenue and macroeconomic pressures on customer spending.
Headwinds
- Significant reduction in high-volume CleanCap sales expected to persist through 2025
- Lower demand in research and discovery products and enzyme offerings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro